Table 2.
Results of ATRX and IDH mutation status stratified by histological diagnosis
| Tumor | WHO Grade | ATRX loss/retention (n)a | IDH mutated/WT (n)a | IDH mutant & ATRX loss/retention (n)a | H3F3A mutant & ATRX loss/retention (n)a |
|---|---|---|---|---|---|
| Diffuse Astrocytoma | 136/120 (53 %) | 156/113 (42 %) | 116/20 (85 %) | ||
| - Low grade | II | 72/49 (59 %) | 86/44 (66 %) | 62/12 (84 %) | |
| - Anaplastic | III | 64/71 (47 %) | 70/69 (50 %) | 52/10 (84 %) | 4/0 (100 %) |
| Oligoastrocytoma | 23/48 (32 %) | 66/6 (92 %) | 23/42 (35 %) | ||
| - Low grade | II | 8/31 (21 %) | 36/3 (92 %) | 8/28 (23 %) | |
| - Anaplastic | III | 15/17 (47 %) | 30/3 (91 %) | 15/14 (52 %) | |
| Oligodendroglioma | 1/79 (1 %) | 81/2 (98 %) | 1/77 (1 %) | ||
| - Low grade | II | 0/33 (0 %) | 35/0 (100 %) | 0/33 (0 %) | |
| - Anaplastic | III | 1/46 (2 %) | 46/2 (96 %) | 1/44 (2 %) | |
| Glioblastoma | IV | 47/260 (15 %) | 38/295 (11 %) | 33/9 (79 %) | 5/7 (42 %) |
| - Primary | IV | 27/215 (11 %) | 19/224 (7 %) | 17/3 (89 %) | 5/7 (42 %) |
| - Secondary | IV | 16/14 (53 %) | 19/11 (63 %) | 14/5 (78 %) | |
| - With oligodendroglial component | IV | 3/10 (23 %) | 4/8 (33 %) | 3/1 (75 %) | |
| - With PNET component | IV | 0/1 (0 %) | 0/1 (0 %) | ||
| - Gliosarcoma | IV | 0/6 (0 %) | 0/6 (0 %) | ||
| Ependymoma | 0/93 (0 %) | 0/98 (0 %) | |||
| - Low grade | II | 0/43 (0 %) | 0/41 (0 %) | ||
| - Anaplastic | III | 0/23 (0 %) | 0/23 (0 %) | ||
| - Myxopapillary | I | 0/18 (0 %) | 0/24 (0 %) | ||
| - Subependymoma | I | 0/9 (0 %) | 0/10 (0 %) | ||
| Pilocytic astrocytoma | I | 0/57 (0 %) | 0/57 (0 %) | ||
| - Pilomyxoid | II | 0/1 (0 %) | 0/1 (0 %) | ||
| - Anaplastic | III | 1/1 (50 %) | 0/2 (0 %) |
aValues in brackets show the percentage of tumors with ATRX loss within the respective sample cohort. For Ependymoma and pilocytic, pilomyxoid and anaplastic pilocytic astrocytoma ony the results of IDH1 (R132)-IHC were available